These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17150008)

  • 1. Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.
    Kowalik S; Minami H; Silva R
    Expert Opin Pharmacother; 2006 Dec; 7(18):2547-57. PubMed ID: 17150008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
    McGough JJ; Pataki CS; Suddath R
    Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Sugrue D; Bogner R; Ehret MJ
    Am J Health Syst Pharm; 2014 Jul; 71(14):1163-70. PubMed ID: 24973373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R; Brams M; Mao A; McCague K; Pestreich L; Silva R
    J Child Adolesc Psychopharmacol; 2008 Jun; 18(3):248-56. PubMed ID: 18582179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
    Drugs R D; 2002; 3(4):279-82. PubMed ID: 12455205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
    Moen MD; Keam SJ
    CNS Drugs; 2009 Dec; 23(12):1057-83. PubMed ID: 19958043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations.
    Patrick KS; Radke JL; Raymond JR; Koller L; Nguyen LV; Rodriguez W; Straughn AB
    Pharmacotherapy; 2019 Jun; 39(6):677-688. PubMed ID: 30351459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
    Childress AC; Spencer T; Lopez F; Gerstner O; Thulasiraman A; Muniz R; Post A
    J Child Adolesc Psychopharmacol; 2009 Aug; 19(4):351-61. PubMed ID: 19702487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Silva RR; Muniz R; Pestreich L; Brams M; Mao AR; Childress A; Wang J
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
    Silva R; Tilker HA; Cecil JT; Kowalik S; Khetani V; Faleck H; Patin J
    J Child Adolesc Psychopharmacol; 2004; 14(4):555-63. PubMed ID: 15662147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
    Arnold LE; Lindsay RL; Conners CK; Wigal SB; Levine AJ; Johnson DE; West SA; Sangal RB; Bohan TP; Zeldis JB
    J Child Adolesc Psychopharmacol; 2004; 14(4):542-54. PubMed ID: 15662146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder.
    Pheils J; Ehret MJ
    Am J Health Syst Pharm; 2021 May; 78(10):840-849. PubMed ID: 33954419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate controlled-delivery capsules (EquasymXL, Metadate CD): a review of its use in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    Paediatr Drugs; 2006; 8(5):319-33. PubMed ID: 17037949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate Formulation, in Healthy Adults and in Adolescents and Children with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Mehrotra S; Gobburu J; McLean A; DeSousa NJ; Incledon B
    J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):10-18. PubMed ID: 29039979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexmethylphenidate.
    Keating GM; Figgitt DP
    Drugs; 2002; 62(13):1899-904; discussion 1905-8. PubMed ID: 12215063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on methylphenidate controlled-delivery capsules (Equasym XL, Metadate CD) in the treatment of children and adolescents with attention-deficit hyperactivity disorder.
    Anderson VR; Keating GM
    CNS Drugs; 2007; 21(2):173-5. PubMed ID: 17284098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.
    Swanson J; Gupta S; Lam A; Shoulson I; Lerner M; Modi N; Lindemulder E; Wigal S
    Arch Gen Psychiatry; 2003 Feb; 60(2):204-11. PubMed ID: 12578439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Formulations of Methylphenidate for the Treatment of Attention-Deficit/Hyperactivity Disorder: Pharmacokinetics, Efficacy, and Tolerability.
    Cortese S; D'Acunto G; Konofal E; Masi G; Vitiello B
    CNS Drugs; 2017 Feb; 31(2):149-160. PubMed ID: 28130762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.